NCT05554926View on ClinicalTrials.gov

Study of [4-14C] AEF0117 Following a Single Oral Dose in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

December 16, 2022

Primary Completion Date

February 24, 2023

Study Completion Date

February 24, 2023

Conditions

Marijuana Abuse

Interventions

DRUG

AEF0117

2 mg AEF0117 containing approximately 100 μCi of \[4-14C\]AEF0117

Trial Locations (1)

53704

Labcorp Clinical Research Unit Inc., Madison

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Aelis Farma

INDUSTRY

NCT05554926 - Study of [4-14C] AEF0117 Following a Single Oral Dose in Healthy Male Subjects | Biotech Hunter | Biotech Hunter